Exelixis director Mary Beckerle sells $526k in shares

Exelixis reported Q2 2026 adjusted EPS of $0.91 (vs. $0.84 consensus) but revenue missed slightly at $628.69M vs. $633.8M, while management lowered full-year 2026 revenue guidance due to a slower NET ramp. Shares reacted negatively, declining after-hours despite continued growth in the CABOMETYX franchise (10% net product revenue growth; cabozantinib franchise revenue ~$806M, ~13% up). Separately, markets pared rate-hike bets after the July CPI release, helping lift stocks overall, even as EXEL turned more cautious on guidance.

Analysis

The market is likely over-weighting the headline guidance cut and under-weighting the composition of growth. The real issue is not a balance-sheet problem or a cliff in the core franchise; it is that incremental growth quality has deteriorated, which usually triggers multiple compression before it shows up in the quarterly P&L. For a mid-cap oncology name, that matters because the stock is priced more on forward duration than on current earnings power.

Second-order, the slower NET ramp creates a nasty mix: the core CABOMETYX base can still look resilient, but investors will now demand proof that new-indication expansion can offset maturity in the legacy base. That tends to cap upside for 1-3 months as sell-side models get cut and generalist holders rotate out, even if the underlying business remains profitable. The 10b5-1 sale is not actionable by itself; it is noise relative to the guidance issue and should not be read as an informed negative signal.

The contrarian read is that the selloff may be larger than the long-term damage if NET is a smaller contributor than the market fears and if partner economics keep compounding outside the U.S. In that case, the stock can stabilize once the revision is fully digested and the focus shifts back to cash generation rather than top-line growth. The falsifier for the bearish view is any evidence in the next two quarters that NET prescriptions reaccelerate or that management can restore full-year guidance without sacrificing margin.

Key Decisions for Investors

• Avoid chasing EXEL weakness immediately; wait for post-guidance model cuts to clear and only consider buying if the stock holds above the low-$50s on volume. Risk/reward is better after estimates reset than on the first flush.
• For accounts that can short single names, initiate a small EXEL short or buy a put spread into any relief rally over the next 1-2 weeks. Target is a 10-15% downside move if the market continues to de-rate growth quality; stop if management evidence suggests NET stabilization.
• Pair trade: long IPSEY / short EXEL for 1-3 months. The thesis is that partner exposure should be less penalized than the originator when the market is focused on U.S. ramp risk; this only works if cabozantinib ex-U.S. trends stay intact.
• Watch the next quarterly prescription commentary and full-year guidance cadence as the key catalyst. If management can show reacceleration in NET or better-than-feared CABOMETYX mix, cover bearish exposure quickly; that would invalidate the multiple-compression thesis.
• No broad sector trade from this alone. Use XBI only as a hedge if you already have biotech exposure, since this is company-specific guidance risk rather than a read-through on the group.